Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Gérald Raverot"'
Autor:
Julien Forestier, Philip Robinson, Catherine Lombard-Bohas, Gérald Raverot, Laurent Milot, Annie Lemelin, Françoise Borson-Chazot, Lucia Hue-Fontaine, Thomas Walter
Publikováno v:
Clinics and Research in Hepatology and Gastroenterology
Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2020, 44, pp.954-960. ⟨10.1016/j.clinre.2020.02.011⟩
Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2020, 44, pp.954-960. ⟨10.1016/j.clinre.2020.02.011⟩
To explore potential synergy in effectiveness between metformin and everolimus, 2 inhibitors of the mTOR pathway, for neuroendocrine tumours (NET).A cohort of patients with advanced gastroenteropancreatic or lung NETs treated by everolimus were strat
Autor:
Guillaume Cadiot, Denis Smith, Thierry Nguyen-Tan-Hon, Brigitte Delemer, F Schillo, Bénédicte Decoudier, Pierre-Luc Etienne, Romain Coriat, Alexandre Santos, Isabelle Raingeard, Ségolène Bisot-Locard, Iradj Sobhani, Gérald Raverot
Publikováno v:
Advances in Therapy. 37:3901-3915
The first long-acting release (LAR) formulation of octreotide was marketed in France in the late 1990s. An injectable formulation of Sandostatin LAR® (Novartis SAS) with a new diluent has been developed to facilitate its preparation and administrati
Autor:
Thierry Brue, Hélène Lasolle, Vincent Amodru, Jacqueline Trouillas, Mirela Diana Ilie, Gérald Raverot, Frederic Castinetti
Publikováno v:
Nature Reviews Endocrinology
Nature Reviews Endocrinology, 2021, 17 (11), pp.671-684. ⟨10.1038/s41574-021-00550-w⟩
Nature Reviews Endocrinology, 2021, 17 (11), pp.671-684. ⟨10.1038/s41574-021-00550-w⟩
Although usually benign, anterior pituitary tumours occasionally exhibit aggressive behaviour, with invasion of surrounding tissues, rapid growth, resistance to conventional treatments and multiple recurrences. In very rare cases, they metastasize an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61532d142f91bc4789374aaa87483b1d
https://hal-amu.archives-ouvertes.fr/hal-03662871
https://hal-amu.archives-ouvertes.fr/hal-03662871
Autor:
Thierry Brue, Philippe Chanson, Patrice Rodien, Brigitte Delemer, Delphine Drui, Lucile Marié, Laurène Juban, Lara Salvi, Robin Henocque, Gérald Raverot
Publikováno v:
Frontiers in Endocrinology
Frontiers in Endocrinology, Frontiers, 2021, 12, ⟨10.3389/fendo.2021.745843⟩
Frontiers in Endocrinology, 2021, 12, ⟨10.3389/fendo.2021.745843⟩
Frontiers in Endocrinology, Vol 12 (2021)
Frontiers in Endocrinology, Frontiers, 2021, 12, ⟨10.3389/fendo.2021.745843⟩
Frontiers in Endocrinology, 2021, 12, ⟨10.3389/fendo.2021.745843⟩
Frontiers in Endocrinology, Vol 12 (2021)
ObjectiveEfficacy of pharmacological treatments for acromegaly has been assessed in many clinical or real-world studies but no study was interested in economics evaluation of these treatments in France. Therefore, the objective of this study was to e
Autor:
Mark E. Molitch, William H. Ludlam, Wenyu Huang, Nienke R. Biermasz, Akexander V Dreval, Elena Isaeva, Nina Leonova, Christian J. Strasburger, Pamela U. Freda, Murray B. Gordon, Gary Patou, Yossi Gilgun-Sherki, Djuro P Macut, Shlomo Melmed, Yulia Pokramovich, Asi Haviv, Irina Bondar, Gérald Raverot, Maria Fleseriu
Publikováno v:
Journal of the Endocrine Society
Background: Injectable somatostatin receptor ligands (iSRLs) have been a mainstay in acromegaly treatment. Oral octreotide capsules (OOC; MYCAPSSA®) were recently approved in the United States. Results from the placebo-controlled CHIASMA OPTIMAL and
Autor:
Robin Henocque, Thierry Brue, Brigitte Delemer, Yves Brault, Christine Cortet-Rudelli, Gérald Raverot, Hervé Lefebvre, Rachel Desailloud, Isabelle Raingeard, Philippe Caron, Sara Barraud, Philippe Chanson
Publikováno v:
Annales d'Endocrinologie
Annales d'Endocrinologie, Elsevier Masson, 2021, 82 (6), pp.582-589. ⟨10.1016/j.ando.2021.05.004⟩
Annales d'Endocrinologie, Elsevier Masson, 2021, 82 (6), pp.582-589. ⟨10.1016/j.ando.2021.05.004⟩
Objective We report the final analysis of the French ACROSTUDY, using data revised and enriched since the 2013 interim analysis. Our objective was to validate the use of pegvisomant (PEGV) in the treatment of acromegaly and to determine efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::256050e0d0ba76fe220f37799c66c569
https://hal.archives-ouvertes.fr/hal-03366670
https://hal.archives-ouvertes.fr/hal-03366670
Publikováno v:
Endocrinology and Metabolism Clinics of North America
Endocrinology and Metabolism Clinics of North America, WB Saunders, 2020, 49, pp.505-515. ⟨10.1016/j.ecl.2020.05.008⟩
Endocrinology and Metabolism Clinics of North America, WB Saunders, 2020, 49, pp.505-515. ⟨10.1016/j.ecl.2020.05.008⟩
A subset of pituitary tumors present an aggressive behavior that remains difficult to predict, and in rare cases they metastasize. The current European Society for Endocrinology (ESE) guidelines for the management of aggressive pituitary tumors and c
Autor:
Ilan Shimon, Thierry Brue, Gérald Raverot, Laura De Marinis, Maria Fleseriu, Mônica R. Gadelha, Pritam Gupta, Annamaria Colao, Jürgen Fleck, Marcello D. Bronstein, Alberto M Pedroncelli, Mirtha Guitelman
Publikováno v:
European Journal of Endocrinology
European Journal of Endocrinology, BioScientifica, 2020, 182 (6), pp.583. ⟨10.1530/EJE-19-0762⟩
European Journal of Endocrinology, 2020, 182 (6), pp.583. ⟨10.1530/EJE-19-0762⟩
European Journal of Endocrinology, BioScientifica, 2020, 182 (6), pp.583. ⟨10.1530/EJE-19-0762⟩
European Journal of Endocrinology, 2020, 182 (6), pp.583. ⟨10.1530/EJE-19-0762⟩
Objective In the Phase III PAOLA study (clinicaltrials.gov: NCT01137682), enrolled patients had uncontrolled acromegaly despite ≥6 months of octreotide/lanreotide treatment before study start. More patients achieved biochemical control with long-ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::199e0366d51d319ae0248fa06ddbaa60
https://hal-amu.archives-ouvertes.fr/hal-03222577
https://hal-amu.archives-ouvertes.fr/hal-03222577
Autor:
Amy Bartalotta, Catalina Poiana, Mônica R. Gadelha, Marisela Jiménez-Sánchez, Serkan Yener, Gérald Raverot, Marie Bex, Rishav Mukherjee, Elier Mitsael Pedroza García, Annamaria Colao, Ricardo Maamari
Publikováno v:
Frontiers in Endocrinology
Frontiers in Endocrinology, Vol 10 (2020)
Frontiers in Endocrinology, Vol 10 (2020)
Introduction: Acromegaly is a rare, serious endocrine disorder characterized by excess growth hormone (GH) secretion by a pituitary adenoma and overproduction of insulin-like growth factor I (IGF-I). Transsphenoidal surgery is the treatment of choice
Publikováno v:
Pituitary. 23(1)
Aggressive prolactinomas are defined as radiologically invasive tumors which cannot be cured by surgery, and that have an unusually rapid rate of tumor growth despite dopamine agonist treatment and surgery. In some cases, metastasis occurs, defining